AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01914822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate hydrochloride
Study NCT01914822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill (placebo)
Study NCT03687021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Different routes of administration of progesterone; Whether there is endometriosis
Study NCT04329650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
Study NCT04329650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
Study NCT03840135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyoxidonium 6 mg/ml
Description: Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours).
Study NCT03840135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours).
Study NCT01416142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision2 HD contact lenses
Description: Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
Study NCT01416142 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Spectacles to be worn throughout 1/2 of an HD movie.
Study NCT01386879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Description: A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
Study NCT01386879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
Study NCT05380622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab.
Study NCT02445989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: Provide NuvaRing to women seeking contraception
Study NCT02445989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Provide NuvaRing to women seeking contraception
Study NCT04283487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructans
Description: 500ml 0.9% normal saline containing 40g fructans
Study NCT04283487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 500ml 0.9% normal saline containing 40g glucose
Study NCT04283487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 500ml 0.9% normal saline
Study NCT02875067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02875067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02059187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study NCT02059187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus™
Description: Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study NCT02059187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial insulin
Description: Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
Study NCT02059187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prandial insulin
Description: Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
Study NCT02221622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone injection (intravenous solution)
Description: Allopregnanolone intravenous infusion
Study NCT02221622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (intravenous solution)
Description: Placebo intravenous infusion
Study NCT02156518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises
Description: Vocal Function Exercises
Study NCT02156518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vocal Hygiene
Description: Vocal Hygiene
Study NCT02465580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hrIL-2 active
Description: active group: placebo group =1:1
Study NCT02465580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hrIL-2 placebo
Description: active group: placebo group =1:1
Study NCT02958748 — intervention group
Intervention type: OTHER
Intervention: taking blood sample
Study NCT02001870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro Fecundation (IVF)
Description: In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
Study NCT02045342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingest 500ml of placebo prior to metabolic measures.
Study NCT04980430 — intervention group
Intervention type: DEVICE
Intervention: Virtual Reality
Description: Virtual Reality Demonstration
Study NCT02001870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra Uterine Insemination (IUI)
Description: Intra-uterine insemination will be performed according to the usual procedure of each ART center
Study NCT01019005 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Catheter
Description: Catheter inserted into either perineural tibial nerve or wound
Study NCT01019005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter
Description: Catheter inserted into either perineural tibial nerve or wound
Study NCT01485510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFT
Description: An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
Study NCT01485510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACS
Description: A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
Study NCT03096418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
Study NCT04380324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Study NCT04380324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Study NCT03933839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCOACH
Description: PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
Study NCT01113294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
Study NCT02197182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUXSOL copper containing cream
Description: Active comparator arm
Study NCT02197182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole gel
Description: Active comparator for treatment of bacterial vaginosis
Study NCT01470586 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery for colorectal cancer
Description: Surgical resection of colorectal cancer
Study NCT00141531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apaziquone
Description: Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis.
Study NCT02454309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry concentrate
Study NCT02454309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02007577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salsalate
Description: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
Study NCT02007577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 3 tablets with breakfast and 4 tablets with dinner
Study NCT01552044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25mg tablet once a day for 1 month
Study NCT00120068 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nursing inservices
Study NCT00120068 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Academic detailing to MDs; concurrent review and feedback
Study NCT03768609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir
Description: Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
Study NCT03768609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
Study NCT01552044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet once a day for 1 month
Study NCT02747342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680; SHR3162
Description: SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase.
Study NCT04351438 — intervention group
Intervention type: DEVICE
Intervention: Active Comparator: centrifuge TPE with citrate
Description: Patients who received citrate-based anticoagulation with centrifuge TPE
Study NCT04351438 — intervention group
Intervention type: DEVICE
Intervention: Active Comparator: Filter TPE with heparin
Description: Patients who received heparin-based anticoagulation with filter TPE
Study NCT04351438 — intervention group
Intervention type: DRUG
Intervention: Active comparator: Filter TPE with citrate
Description: Patients who received citrate-based anticoagulation with filter TPE
Study NCT02532218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARI-3037MO
Description: Lipid lowering treatment Statins
Study NCT02532218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARI-3037MO
Description: Lipid lowering treatment Statins
Study NCT03806985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: microcrystalline cellulose capsule
Study NCT03806985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
Study NCT03806985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
Study NCT05535595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genotyping and selection of renin-angiotensin system blocker
Description: One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping
Study NCT05535595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: perindopril 4 mg/d without genotyping
Study NCT04575974 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02751086 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Gastrectomy
Description: Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
Study NCT01964573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily
Study NCT01964573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily
Study NCT04327466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osciflow
Description: Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
Study NCT04327466 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Highflow
Description: Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
Study NCT04302792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texture-modified foods for cancer patients (Stage 2)
Description: Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
Study NCT04302792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste-optimised foods for cancer patients (Stage 3)
Description: Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
Study NCT03663751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: low-dose decitabine: 5mg/m2 daily for 5 days
Study NCT02319499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Alone
Description: Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
Study NCT02319499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Zinc
Description: Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
Study NCT02319499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron, Zinc and Vitamin A
Description: Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
Study NCT02319499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group received no minerals/vitamin
Study NCT04544462 — intervention group
Intervention type: OTHER
Intervention: M2 Test
Description: DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
Study NCT02751086 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Gastrectomy
Description: Minimally invasive surgical approach performed through traditional laparoscopy.
Study NCT00853931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
Study NCT01347879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visonac PDT
Description: cream application prior to illumination with red light
Study NCT01347879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream with PDT
Description: placebo/vehicle cream application prior to illumination with red light
Study NCT01135108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV Infusion
Study NCT01135108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-1678
Description: KAI-1678 IV Infusion
Study NCT01047904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Iontophoresis System
Description: Administration of local anesthesia using the Acclarent Iontophoresis System
Study NCT03631459 — intervention group
Intervention type: DRUG
Intervention: Kanglaite Injection/Capsules
Description: Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
Study NCT04208191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: Facilities that participated in a QI collaborative to improve PCC for MH and FP services
Study NCT03351127 — intervention group
Intervention type: RADIATION
Intervention: Carotid ultrasound examination
Description: Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
Study NCT01389024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
Study NCT01389024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
Study NCT03586037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg
Description: AD-2011 10/20 mg tablet
Study NCT03586037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2012 80mg
Description: AD-2012 80mg tablet
Study NCT03586037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2011 10/20 mg + AD-2012 80mg
Description: AD-2011 10/20 mg + AD-2012 80mg tablet
Study NCT02361853 — intervention group
Intervention type: OTHER
Intervention: Exposure: abundance of Immature Myeloid Cells counts in blood samples
Study NCT02361853 — intervention group
Intervention type: OTHER
Intervention: Exposure: abundance of Immature Dentritic Cells counts in blood samples
Study NCT02361853 — intervention group
Intervention type: OTHER
Intervention: Exposure: abundance of Immature monocytes counts in blood samples